PF-Atlas › Clinical Trials › NCT02257177
RCT of TD139 vs Placebo in HV's and IPF Patients
Inhaled TD139 · Phase 1
Registry ID
NCT02257177
Phase
Phase 1
Status
Completed
Drug / intervention
Inhaled TD139
Sponsor
Galecto Biotech AB
Start
2014-09
Enrollment
60
Locations
5
About this trial
This study will be divided into 2 parts. Part 1 is a randomized, double-blind, single centre, placebo-controlled, single ascending dose (SAD) phase I study designed to assess the safety, tolerability, PK and PD (Pharmacodynamic) of TD139 in up to 36 healthy male subjects. Part 2 will be a randomized, double-blind, multi-centre, placebo-controlled, multiple dose expansion cohort, designed to assess the safety, tolerability, PK and PD of TD139 in up to 24 male subjects and female subjects of non child-bearing potential with IPF.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02257177 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.